Key result
Clopidogrel therapy in patients undergoing percutaneous coronary intervention significantly reduced median serum hs-CRP levels from 14 mg/L at baseline to 3.8 mg/L at 12 weeks.
Why the study?
Does clopidogrel therapy reduce hs-CRP levels in patients undergoing percutaneous coronary intervention?
Population
650 consecutive patients undergoing elective, urgent, or emergent percutaneous coronary intervention, mean…
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Clopidogrel-associated hs-CRP reduction post-PCI is hypothesis-generating; leaves open impact on clinical outcomes.
Observational (n=650)
Yes
Does clopidogrel therapy reduce hs-CRP levels in patients undergoing percutaneous coronary intervention?
p-value: p=<0.001
Clopidogrel therapy significantly reduces hs-CRP levels over 12 weeks in patients undergoing PCI, suggesting an anti-inflammatory effect that is particularly pronounced in patients with diabetes and hypertension.
Hajsadeghi et al. (2015) conducted an observational in Percutaneous coronary intervention (PCI) (n=650). Clopidogrel was evaluated on Median serum hs-CRP level at 12 weeks (mg/L) (p=<0.001). Clopidogrel therapy in patients undergoing percutaneous coronary intervention significantly reduced median serum hs-CRP levels from 14 mg/L at baseline to 3.8 mg/L at 12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: